Attempts to inhibit BRG1 and/or BRM may be particularly important in the treatment of triple-negative or ER/PR-negative and HER2-low to normal breast cancer, especially in cases where targeted therapy is not feasible and patients can only benefit from low-targeted cytotoxic drugs. The gene discussed is SMARCA2; the disease is breast cancer.